Radboud UMC
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bussink, J
IMMUNOSABR2, NCT03705403 / 2018-002583-11: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

Active, not recruiting
2
88
Europe
Darleukin, L19 - IL2, Radiation, Radiotherapy
Maastricht University Medical Center, Academisch Ziekenhuis Maastricht, The Netherlands Cancer Institute, University Medical Center Nijmegen, Erasmus Medical Center, University Ghent, KU Leuven, Centre Oscar Lambret, Gasthuis Zusters Antwerpen, University College, London, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital Dresden, University Hospital Tuebingen, Heidelberg University, Catholic University of the Sacred Heart, Institut du Cancer de Montpellier - Val d'Aurelle
NSCLC Stage IV, Metastatic Disease
01/25
01/25
CLARIFY, NCT03978377: Cardiopulmonary Toxicity of Thoracic Radiotherapy

Recruiting
N/A
320
Europe
University Medical Center Groningen
Oesophageal Cancer, Non Small Cell Lung Cancer
04/25
04/26

Download Options